Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Hypothetical scenario

<< Previous

Bullboard Posts

Next >>

Comment by muto412on Oct 14, 2021 9:39am

348 Views

Post# 34004607

RE:RE:Hypothetical scenario

I think it's nice to have an understanding of where the company is headed. I can't help but be frustrated once again by the vaugeness of their news releases.

This quote has me particularly annoyed:
"Importantly, given the relatively short trials required, we feoresee a faster path to market than originally envisaged with our chronic pain program."

"relatively short or faster path" - you've got to be kidding me. Give me specifics for sticking with this company for 6 years...Dan may be an excellent strategist, but his communication style/skills are trash. Now is when we need someone who can communicate at a depth the market needs to understand this space...

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading